Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
Top Cited Papers
- 15 February 2013
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 381 (9865), 468-475
- https://doi.org/10.1016/s0140-6736(12)61425-1
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Hepatocellular CarcinomaThe New England Journal of Medicine, 2011
- Obesity is an independent risk factor for clinical decompensation in patients with cirrhosisJournal of Hepatology, 2011
- Diagnosis and Quantitation of FibrosisGastroenterology, 2008
- Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 YearsGastroenterology, 2006
- Reversibility of hepatic fibrosis in treated genetic hemochromatosis: A study of 36 casesJournal of Hepatology, 2006
- Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral LoadGastroenterology, 2006
- The relationship between HBV‐DNA levels and cirrhosis‐related complications in Chinese with chronic hepatitis BJournal of Viral Hepatitis, 2005
- Sampling variability of liver fibrosis in chronic hepatitis CJournal of Hepatology, 2003
- Histological grading and staging of chronic hepatitisJournal of Hepatology, 1995
- Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitisJournal of Hepatology, 1981